Hofman et al., 2016 - Google Patents
Pathologists and liquid biopsies: to be or not to be?Hofman et al., 2016
- Document ID
- 15122387228480055434
- Author
- Hofman P
- Popper H
- Publication year
- Publication venue
- Virchows Archiv
External Links
Snippet
Recently, the advent of therapies targeting genomic alterations has improved the care of patients with certain types of cancer. While molecular targets were initially detected in nucleic acid samples extracted from tumor tissue, detection of nucleic acids in circulating …
- 238000001574 biopsy 0 title abstract description 77
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/28—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6802—General aspects
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hofman et al. | Pathologists and liquid biopsies: to be or not to be? | |
Piccioni et al. | Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors | |
Rose Brannon et al. | Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS | |
Kwan et al. | A digital RNA signature of circulating tumor cells predicting early therapeutic response in localized and metastatic breast cancer | |
US11415571B2 (en) | Large scale organoid analysis | |
Beltran et al. | Whole-exome sequencing of metastatic cancer and biomarkers of treatment response | |
US20180060482A1 (en) | Interpreting genomic results and providing targeted treatment options in cancer patients | |
Eszlinger et al. | Molecular profiling of thyroid nodule fine-needle aspiration cytology | |
Hayes et al. | Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts | |
Kerr et al. | Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? | |
Xie et al. | Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non–small-cell lung cancer patients | |
de Wit et al. | Single tube liquid biopsy for advanced non‐small cell lung cancer | |
Luke et al. | Realizing the potential of plasma genotyping in an age of genotype-directed therapies | |
Garutti et al. | Definition of high-risk early hormone-positive HER2− Negative breast cancer: a consensus review | |
US20220392640A1 (en) | Systems and methods for predicting therapeutic sensitivity | |
Borowczyk et al. | Differences in mutational profile between follicular thyroid carcinoma and follicular thyroid adenoma identified using next generation sequencing | |
Bins et al. | Implementation of a multicenter biobanking collaboration for next‐generation sequencing‐based biomarker discovery based on fresh frozen pretreatment tumor tissue biopsies | |
Iwase et al. | A novel immunomodulatory 27-gene signature to predict response to neoadjuvant immunochemotherapy for primary triple-negative breast cancer | |
Berry et al. | Reviewing the utility of EUS FNA to advance precision medicine in pancreatic cancer | |
Öberg | Molecular genomic blood biomarkers for neuroendocrine tumors: the long and winding road from berzelius and bence jones to a neuroendocrine destination | |
Bingham et al. | PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry | |
Hofman et al. | Predictive molecular pathology in non–small cell lung cancer in France: The past, the present and the perspectives | |
Barbirou et al. | Single circulating-tumor-cell-targeted sequencing to identify somatic variants in liquid biopsies in non-small-cell lung cancer patients | |
AACR Pathology Task Force Compton Carolyn C. De Marzo Angelo M. Debnath Jayanta Eaton Keith D. Elenitoba-Johnson Kojo Fiorentino Michelangelo French Christopher A. Fuchs Thomas J. Giangaspero Felice Huang Jiaoti Iafrate A. John Ittmann Michael M. Jensen Roy A. Kim Annette S. Loda Massimo* Lorenz Robin G. Lotan Tamara L. Maitra Anirban Meijer Gerrit A. Mitchell Richard N. Parwani Anil V. Pezzella Francesco Pikarsky Eli Reis-Filho Jorge S. Richardson Andrea L. Rubin Mark A. True Lawrence D.* | Pathology: hub and integrator of modern, multidisciplinary [precision] oncology | |
Froelich et al. | The value proposition of integrative diagnostics for (early) detection of cancer. On behalf of the EFLM interdisciplinary Task and Finish Group “CNAPS/CTC for early detection of cancer” |